Consistently, within the TARGET-AML cohort, patients who have over the median score of Regen71 (REC+) and LSC17 (LSC+) have dismal EFS and worse ELN stratifications compared with REC+/LSC−, LSC+/REC−, and REC−/LSC− patients (Figures S5D and S5E). Here, ARHGEF1 is linked to acute myeloid leukemia.